US higher education faces $7 billion hit as international commencements set to drop by 40% this September
A new analysis forecasts a significant downturn in international student commencements in the US this fall, with projected declines of 30% to 40% for September 2025. The data, jointly produced by NAFSA and research consultancy JB International, highlights a potential loss of up to 150,000 international students, driven largely by visa processing backlogs during the peak May–August window.
The projected decline would translate into a 15% reduction in international enrolments for the 2025/26 academic year compared to the previous year. According to the NAFSA/JB International study, this would have an estimated economic impact of US$7 billion and affect over 60,000 jobs across the country.
Visa delays and travel restrictions behind enrolment decline
The study attributes the projected decline to four primary factors: the suspension of student visa interviews from May 27 through June 18, limited visa appointment availability after that suspension was lifted, a softening trend in visa issuance through early 2025, and travel restrictions impacting multiple sending markets.
As per data reported by the ICEF, F-1 visa issuance declined by 12% from January through April 2025 compared to the same period in 2024. The drop was more severe in May 2025, when F-1 issuances fell by 22%. JB International CEO Jason Baumgartner noted that "we might be looking at as much as an 80–90% decline in visa issuance for the month of June,' due to the pause and delays in restoring full processing.
NAFSA CEO Fanta Aw stated that, 'The issue doesn't seem to be one of capacity at US embassies, because we see high volumes of visas [across all categories] issued,' as quoted by the ICEF.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Citizens Advice: 3M Brits Miss £520 for Flight Delays – Are You Eligible?
Flight Compensation
Undo
'Where the problem seems to reside is around international students in particular.'
Travel bans affecting major sending countries
The report also cited new US travel policies as a contributing factor. On June 4, the US administration implemented a full travel ban for 12 countries and a partial ban on citizens from another seven. Additionally, the government indicated it was considering similar restrictions on travelers from 36 more countries, including key student markets in Africa.
NAFSA also flagged limited appointment availability in countries such as India, China, Nigeria, and Japan, all of which represent major sources of international students for US institutions.
Actual and projected international student enrolment and economic impact in the United States, 2020/21–2025/26.
• Green bars represent total dollars.
• Orange line (with squares) shows the number of students.
• Dark blue line (with squares) indicates the number of jobs.
Source: NAFSA/JB International
Economic and enrolment implications
The following table summarizes the projected changes and their estimated impacts:
Metric
Projected Impact
Decline in new international students
30–40% (up to 150,000)
Reduction in total enrolment (2025/26)
15%
Economic loss
US$7 billion
Jobs affected
Over 60,000
Stakeholders urge government intervention
NAFSA has called on the US Department of State to expedite visa processing and prioritize F-1, M-1, and J-1 applicants. In addition, the association has urged that these categories be exempted from travel bans, while maintaining standard security vetting procedures.
On July 24, 15 Members of Congress issued a letter to Secretary of State Marco Rubio, requesting clarification on what the department is doing to resolve visa backlogs, particularly in India. 'We are dismayed at the possibility that many of these bright young individuals may be blocked... from continuing their education and research in the United States,' the letter states, as reported by the ICEF.
TOI Education is on WhatsApp now. Follow us
here
.
Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Pharma Inc gear up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
Time of India
19 hours ago
- Time of India
RPCAU develops 3 maize varieties suited for Bihar's conditions
Patna: In a major stride for agricultural innovation, scientists at Rajendra Prasad Central Agricultural University (RPCAU) have unveiled three new maize varieties poised to transform maize cultivation across eastern India. The newly introduced varieties include, Rajendra Baby Corn-1 – a region-specific baby corn hybrid tailored for Bihar's agro-climatic conditioSns; Rajendra Pop Corn-1 – a high-yielding popcorn hybrid, and Shaktiman-5 – a biofortified quality protein maize. Developed by the maize breeding team at Tirhut College of Agriculture (TCA), Dholi, Rajendra Baby Corn-1 is expected to offer a profitable and sustainable crop alternative for small and marginal farmers. "Baby corn enjoys strong market demand, particularly in urban areas and food processing industries. However, a hybrid suited to Bihar's unique conditions was missing. Our aim was to bridge that gap," said maize scientist Ajay Kumar. What makes this hybrid exceptional is its short growing duration and ready to harvest in just two months and its ability to produce 12 to 15 quintals per hectare of fresh baby corn, along with 200–300 quintals per hectare of green fodder, making it a dual-purpose crop. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas in Dubai | Search Ads Get Info Undo Experts believe that this innovation can significantly contribute to the state's goal of crop diversification, doubling farmers' income, and establishing agro-processing linkages. For farmers seeking quick returns, nutrition, and market potential, Rajendra Baby Corn-1 is not just a variety — it's an opportunity. The Rajendra Pop Corn-1 variety is specially tailored for Bihar's agro-climatic conditions. It offers farmers an attractive alternative to traditional grain maize, with the added advantage of tapping into the growing demand for packaged popcorn in urban markets. This hybrid variety matures in just 80 to 90 days, making it suitable for Rabi and late Kharif seasons. It yields up to 30-40 quintals per hectare, outperforming several existing varieties. Most impressively, it boasts a popping expansion ratio of 34–36 cc/g and a popping percentage of over 95%, producing soft, butterfly-type flakes ideal for commercial sale. The biofortified 'Shaktiman-5' variety offers a unique solution to a dual challenge faced in eastern India: protein malnutrition and low farm returns. It has been bred to contain elevated levels of lysine and tryptophan, essential amino acids often lacking in conventional maize. These nutrients are vital for human growth, immune function, and child development, particularly in regions where cereals dominate the diet. Beyond its agronomic merits, Shaktiman-5 is aligned with key national priorities such as PoshanAbhiyan, the National Biofortification Mission, and the Public Distribution System (PDS). It as an ideal food for mid-day meal schemes, anganwadi nutrition programmes, and livestock feed improvement, said RPCAU vice-chancellor P S Pandey. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
Time of India
20 hours ago
- Time of India
Learn this money trick from the rich: Understand the power of compounding and discounting to grow your money
Why these concepts matter? Academy Empower your mind, elevate your skills Impact of inflation ET Bureau Fun shortcuts This rule provides an estimate of how long it will take to quadruple your investment. At a 10% interest rate, it will take 14.4 years for an investment to grow 4 times. You may look at Table 1 to verify these rules. The multiple is 2.01 at 5 years, indicating Rs.1 will turn into Rs.2 at the end of 5 years (approximately) at a 15% interest rate. Similarly, the multiple is 4.18 at 10% for 15 years, indicating the investment will grow 4 times in around 15 years. This is a useful rule for predicting your future buying power. The rule of 70 helps you estimate how much your money will be worth in the future. Simply divide 70 by the current inflation rate. This will tell you how long it will take for the value of the rupee to be cut in half. At 4% inflation rate, the rupee will lose half of its purchasing power in 17.5 years. This is specially important for retirement plans, as it may affect the way one chooses to set up monthly withdrawals. Ever wonder how financial experts work out numbers to address the personal finance queries of their clients? The two concepts—compounding and discounting—play a critical role in calculations for personal finance management . While the former helps to calculate how much the investment will grow in the future, the latter determines how much future cash flow is worth these concepts are based on the 'time value of money,' which holds that money available today is more valuable than the same amount received in the future, due to its potential earning capacity. For example, Rs.100 received today can be invested at a 7% rate and will become Rs.107 after a such as income stability, spending habits, debt levels, inflation and interest rate fluctuations , and broader macroeconomic changes influence money management. Compounding and discounting aid this process by supporting budgeting, risk assessment, asset valuation, and overall financial addition, compounding helps investors to understand the benefits of long-term investing , early savings, consistency, and reinvestment gains. On the other hand, discounting assists in assessing the viability of different investment options, evaluating the impact of inflation, and estimating the fair value of of delving into the mathematics of compounding and discounting, we tried to demonstrate its applications by creating various numbers presented in Table 1 and Table 2 are calculated assuming Rs.1 is invested, whereas Table 3 and 4 are also based on annual expenditures and purchasing power of Rs.1. Therefore, these numbers can be used as multipliers for determining the maturity or purchasing value of any amount. Table 5 includes absolute values that cannot be used as works by adding interest back to the principal. The subsequent interest amount is then calculated on the new principal amount. By continuously reinvesting the earnings, compounding allows the value of an investment to grow at an increasing rate. The level of interest rate, time horizon, and frequency of compounding play a key role in magnifying the effect of investments can be made in a lump sum (fixed deposits, National Saving Certificates) or one-time in stocks or mutual funds, or can be spread over time (recurring deposits or mutual fund SIPs). So, Rs.1 lakh invested for 5 years at 8% interest rate has a maturity value of Rs.1.47 lakh (Rs.1 lakh x 1.47), whereas the same amount if invested for 20 years will grow to Rs.4.66 lakh. The benefit of compounding becomes evident as time the interest rate also helps in accelerating the growth; however, the impact is more pronounced in the later years. For a strong compounding effect, a longer tenure and a higher interest rate are 2 helps in finding out the maturity value of periodic (monthly) investments for different tenures and interest rates. One can multiply the monthly investments to find the maturity value. For example, an investment of Rs.20,000 per month at a 10% interest rate for 24 months will create a maturity value of Rs.5.29 lakh (20,000 x 26.45).The table highlights the importance of starting early investments. Even with modest returns, investors who have started investments early can create substantial wealth over investor with a 10-year time horizon (120 months) and investing Rs.30,000 per month at a modest rate of 8% per annum can create Rs.54.9 lakh wealth compared to an investor that has a 5-year (60 months) time horizon. Even at a higher rate of 15%, the investor with a 5-year horizon will accumulate only Rs.26.57 or the general increase in the price level, can jeopardize the calculations, especially for long-term (retirement) goals. This is because higher inflation reduces the purchasing power of money and creates an income-expenditure mismatch. While the income is affected as it loses value (can purchase a lesser quantity of goods), the expenses swell due to an increase in the prices of essentials like food, fuel, healthcare, and education.A household with an annual expenditure of Rs.3 lakh a year will grow to Rs.4.44 lakh per year (Rs.3 lakh x 1.48) after 10 years if inflation averages 4% every year. At a higher inflation rate of 5%, the annual expenses will swell to Rs.4.89 lakh after 10 years.: It is the inverse of compounding that translates the money receivable in the future to its present value. The rate used to convert the future money into its present value is termed the discounting concept is based on the premise that time reduces the value of money because of inflation, uncertainty, and opportunity cost (availability of investment options). Generally, the larger the time and discount rate, the lower the present purchasing power of Rs.100 at a 4% average inflation rate will be reduced to Rs.68 after 10 years. As one can observe, the higher inflation rate and longer time create a larger contraction in the purchasing power (or present value). Therefore, investments must grow at a rate higher than the inflation present value proves useful in retirement planning by estimating how much one needs to save to meet future numbers highlight the importance of financial discipline. A person with more years left for retirement (implying more years for investment) requires lower 30 years to retirement, an investment of Rs.2,861 is needed every month at a 12% annualised interest rate to accumulate Rs.1 crore. Comparatively, if starting 5 years later, to accumulate Rs.1 crore at a 12% rate, an investor needs to invest Rs.5,322 every month, which is 86% higher. The amount needed every month continues to swell as the investment is finance has some mental math shortcuts that help with quick calculations. Though the calculations are not exact, they provide close approximates. Some of these shortcuts:This helps to calculate the number of years it will take to double the money. Simply take 72 and divide it by the interest rate. For example, at a 15% interest rate, it will take 4.8 years (or close to 5 years) to double the to know how long it will take to triple your money? Use the rule of 114. It works in the same way as the rule of 72. Simply divide 114 by your interest rate to determine how long it will take for your money to triple. At a 10% interest rate, it will take 11.4 years to triple your money.
